PDGFRB and leukemia: Most importantly, alpelisib therapy in NSGS mice bearing nilotinib-resistant K562 cells significantly reduces leukemia burden and increases the survival time of leukemic mice, mechanistically through suppression of PI3K signaling mediators like F2R, Cyclin D1, and PDGFR.